S-adenosyl-L-methionine-competitive inhibitors of the histone methyltransferase EZH2 induce autophagy and enhance drug sensitivity in cancer cells

Anti-Cancer Drugs

Volumn 26, Issue 2, 2015, Pages 139-147

  Liu, Tsang Pai ^a,b,c,d   Lo, Hsiang Ling ^a   Wei, Li Shan ^b   Hsiao, Heidi Hao Yun ^a   Yang, Pei Ming ^a  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b MACKAY MEMORIAL HOSPITAL   (Taiwan)

^c NURSING AND MANAGEMENT COLLEGE   (Taiwan)

^d MACKAY MEDICAL COLLEGE   (Taiwan)

Author keywords

Autophagy; Cancer; EZH2; S adenosyl L methionine

Indexed keywords

3 DEAZANEPLANOCIN A; ANTINEOPLASTIC AGENT; BERBERINE; CASPASE 3; DOXORUBICIN; ETOPOSIDE; GSK 343; METHYLTRANSFERASE INHIBITOR; PACLITAXEL; PROTEIN P62; S ADENOSYLMETHIONINE; SORAFENIB; TRANSCRIPTION FACTOR EZH2; UNC 1999; UNCLASSIFIED DRUG; VORINOSTAT; 3-DEAZANEPLANOCIN; ADENOSINE; CARBANILAMIDE DERIVATIVE; ENZYME INHIBITOR; EZH2 PROTEIN, HUMAN; GSK343; HISTONE LYSINE METHYLTRANSFERASE; HISTONE METHYLTRANSFERASE; INDAZOLE DERIVATIVE; NICOTINAMIDE; POLYCOMB REPRESSIVE COMPLEX 2; PYRIDONE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; BREAST CANCER; CANCER CELL CULTURE; CELL VACUOLE; CELL VIABILITY; COMPARATIVE EFFECTIVENESS; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG POTENCY; DRUG POTENTIATION; DRUG SENSITIVITY; FLUORESCENCE MICROSCOPY; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; LUNG CANCER; LYSOSOME; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; DRUG EFFECTS; GENETICS; HEPG2 CELL LINE; METABOLISM; TUMOR CELL LINE;

ADENOSINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUTOPHAGY; CELL LINE, TUMOR; CELL SURVIVAL; ENZYME INHIBITORS; GENE KNOCKDOWN TECHNIQUES; HEP G2 CELLS; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; INDAZOLES; NIACINAMIDE; PHENYLUREA COMPOUNDS; POLYCOMB REPRESSIVE COMPLEX 2; PYRIDONES; S-ADENOSYLMETHIONINE;

EID: 84937402450     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000166     Document Type: Article

References (30)

1. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 2003;100:11606-11611.
2. Raaphorst FM, Meijer CJ, Fieret E, Blokzijl T, Mommers E, Buerger H, et al. Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene. Neoplasia 2003;5:481-488.
3. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002;419:624-629.
4. Van der Vlag J, Otte AP. Transcriptional repression mediated by the human polycomb-group protein EED involves histone deacetylation. Nat Genet 1999;23:474-478.
5. Croonquist PA, Van Ness B. The polycomb group protein enhancer of zeste homolog 2 (EZH 2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype. Oncogene 2005;24:6269-6280.
6. Tan J, Yang X, Zhuang L, Jiang X, Chen W, Lee PL, et al. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 2007;21:1050-1063.
7. Tan JZ, Yan Y, Wang XX, Jiang Y, Xu HE. EZH2: biology, disease, and structure-based drug discovery. Acta Pharmacol Sin 2014;35:161-174.
8. Knutson SK, Wigle TJ, Warholic NM, Sneeringer CJ, Allain CJ, Klaus CR, et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol 2012;8:890-896.
9. McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 2012;492:108-112.
10. Qi W, Chan H, Teng L, Li L, Chuai S, Zhang R, et al. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc Natl Acad Sci USA 2012;109:21360-21365.
11. Verma SK, Tian X, LaFrance LV, Duquenne C, Suarez DP, Newlander KA, et al. Identification of potent, selective, cell-active inhibitors of the histone lysine methyltransferase EZH2. ACS Med Chem Lett 2012;3:1091-1096.
12. Meijer AJ, Dubbelhuis PF. Amino acid signalling and the integration of metabolism. Biochem Biophys Res Commun 2004;313:397-403.
13. Levine B. Cell biology: autophagy and cancer. Nature 2007;446:745-747.
14. Levine B, Deretic V. Unveiling the roles of autophagy in innate and adaptive immunity. Nat Rev Immunol 2007;7:767-777.
15. Klionsky DJ, Cregg JM, Dunn WA Jr, Emr SD, Sakai Y, Sandoval IV, et al. A unified nomenclature for yeast autophagy-related genes. Dev Cell 2003;5:539-545.
16. Tanida I, Ueno T, Kominami E. LC3 conjugation system in mammalian autophagy. Int J Biochem Cell Biol 2004;36:2503-2518.
17. Miranda TB, Cortez CC, Yoo CB, Liang G, Abe M, Kelly TK, et al. DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol Cancer Ther 2009;8:1579-1588.
18. Simon JA. Stopping a chromatin enzyme. Nat Chem Biol 2012;8:875-876.
19. Maiuri MC, Zalckvar E, Kimchi A, Kroemer G. Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol 2007;8:741-752.
20. Bjorkoy G, Lamark T, Brech A, Outzen H, Perander M, Overvatn A, et al. p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death. J Cell Biol 2005;171:603-614.
21. Xie R, Nguyen S, McKeehan WL, Liu L. Acetylated microtubules are required for fusion of autophagosomes with lysosomes. BMC Cell Biol 2010;11:89.
22. Konze KD, Ma A, Li F, Barsyte-Lovejoy D, Parton T, MacNevin CJ, et al. An orally bioavailable chemical probe of the lysine methyltransferases EZH2 and EZH1. ACS Chem Biol 2013;8:1324-1334.
23. Wang S, Zhu Y, He H, Liu J, Xu L, Zhang H, et al. Sorafenib suppresses growth and survival of hepatoma cells by accelerating degradation of enhancer of zeste homolog 2. Cancer Sci 2013;104:750-759.
24. Knutson SK, Warholic NM, Wigle TJ, Klaus CR, Allain CJ, Raimondi A, et al. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc Natl Acad Sci USA 2013;110:7922-7927.
25. Chiang PK, Gordon RK, Tal J, Zeng GC, Doctor BP, Pardhasaradhi K, McCann PP. S-Adenosylmethionine and methylation. FASEB J 1996;10:471-480.
26. Sutter BM, Wu X, Laxman S, Tu BP. Methionine inhibits autophagy and promotes growth by inducing the SAM-responsive methylation of PP2A. Cell 2013;154:403-415.
27. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94:153-156.
28. Roberts LR, Gores GJ. Hepatocellular carcinoma: molecular pathways and new therapeutic targets. Semin Liver Dis 2005;25:212-225.
29. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
30. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebocontrolled trial. Lancet Oncol 2009;10:25-34.